REGENXBIO Inc. (RGNX) Stock Price & Analysis
REGENXBIO Inc. (RGNX) closed at USD 7.41 on Thursday, October 29, 2026, up 2.35% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 7.24; the Oct 29, 2026 session ranged USD 7.21–7.63 on volume of 1,033,249 shares. Market capitalization is $489.16M, with a 52-week range of USD 5.46–16.19 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:59 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RGNX.md
Key facts (RGNX)
- Last four reported quarters (through Jun 30, 2026): revenue $174M, net income -$196M (-112.6% margin), free cash flow -$250M (SEC filings).
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $887K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $949K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 23.58 (range 10–50).
- Total return with dividends: 1Y -42.2% vs S&P 500 +14.4%; 5Y -79.1% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.3, revenue estimate $15.7M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RGNX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $470M | $113M | $90.2M | $83.3M | $170M | $174M |
| Gross profit | $419M | $58.2M | $53.0M | $49.8M | — | — |
| Operating income | $160M | -$263M | -$268M | -$233M | -$161M | -$164M |
| Net income | $128M | -$280M | -$263M | -$227M | -$194M | -$196M |
| EPS (diluted) | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 | — |
| Free cash flow | $135M | -$238M | -$228M | -$176M | -$126M | -$250M |
| Gross margin | 89.0% | 51.6% | 58.8% | 59.7% | — | — |
| Operating margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% | -94.1% |
| Net margin | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% | -112.6% |
| Revenue growth | +204.3% | -76.0% | -19.9% | -7.7% | +104.5% | — |
| Cash + short-term investments | $849M | $565M | $314M | $245M | $241M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RGNX)
P/S 2.8x · P/B 6.8x · FCF yield -51.04% · Earnings yield -40.16%
Insider sales (SEC Form 4, open-market, last ~7 months) (RGNX)
3 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Pakola Steve | Chief Medical Officer | 2,161 | $29K | 1% | Yes | Too little history (no open-market trades in 2025) |
| 2026-06-29…2026-07-01 | Pakola Steve | Chief Medical Officer | 56,333 | $689K | 20.9% | Yes | Too little history (no open-market trades in 2025) |
| 2026-05-11 | Pakola Steve | Chief Medical Officer | 15,309 | $169K | 6.2% | Yes | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (RGNX)
1 purchase, $949K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-26…2026-08-27 | Ciongoli Gregory Austin | Director | 102,603 | $949K | 9.25 | Too little history (no open-market trades in 2023–2025) |
Analysts (RGNX)
Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 23.58 (low 10, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Mizuho | Initiated | Outperform | $22 |
| 2026-08-25 | HC Wainwright & Co. | Target lowered | Buy | $23 → $21 |
| 2026-08-25 | Baird | Target lowered | Outperform | $32 → $29 |
| 2026-08-10 | HC Wainwright & Co. | Target lowered | Buy | $26 → $23 |
| 2026-08-07 | Barclays | Downgrade | Overweight → Equal-Weight | $12 |
Total return (dividends reinvested) (RGNX)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -42.2% | -79.1% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -42.3% | -26.8% |
| Volatility (annualized) | 97.1% | 73.4% |
| Max drawdown | -64.6% (Jan 2026→May 2026) | -85.4% (Nov 2021→May 2026) |
RGNX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | $0.43 | −$0.11 | Beat +$0.54 | +2.1% |
| May 14, 2026 | Quarter ended Mar 31, 2026 | −$1.72 | −$1.41 | Miss −22.0% | -43.0% |
| Mar 5, 2026 | Quarter ended Dec 31, 2025 | −$1.30 | −$0.84 | Miss −54.8% | -5.4% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$1.20 | −$1.30 | Beat +7.7% | -3.4% |
| Aug 7, 2025 | — | — | — | — | -4.6% |
| May 12, 2025 | — | — | — | — | +8.8% |
| Mar 13, 2025 | — | — | — | — | +0.7% |
| Nov 6, 2024 | — | — | — | — | +25.4% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RGNX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 16, 2026 | 8-K | Director or executive officer change, or pay arrangement “On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the "Board") of REGENXBIO Inc. (the "Company") effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role. Mr. Mills' decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices. In connection with Mr. Mills' departure, the Board appointed George Migausky as Chairman of the Board…” |
| Oct 13, 2026 | Schedule 13G | JPMORGAN CHASE & CO.: 5.3% of shares, passive 5%+ holder |
| Sep 23, 2026 | 8-K | Entered a material agreement “On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., "Sarepta") and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. Patent No. 10,526,617 (the "617 patent") and U.S. Patent No. 11,680,274 (the "274 patent") (together with the 617 patent,…” |
| Aug 25, 2026 | 8-K | Director or executive officer change, or pay arrangement “On August 25, 2026, the Board of Directors (the "Board") of REGENXBIO Inc. (the "Company"), elected Gregory Ciongoli as a Class II director of the Company effective immediately. Mr. Ciongoli's initial term will expire at the Company's 2029 annual meeting of stockholders. The Board has determined that Mr. Ciongoli is an independent director in accordance with applicable rules of the U.S. Securities and Exchange Commission (the "SEC") and the Nasdaq Global Select Market. The Board also appointed Mr. Ciongoli as a…” |
| Aug 24, 2026 | 8-K | Regulation FD disclosure; Other material event “On August 24, 2026, the Company announced that it received communication from the FDA that the Company's Investigational New Drug application for its Phase I/II/III trial of RGX-121 for MPS II was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 BLA in the near term.” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Jul 20, 2026 | 8-K | Other material event “On July 16, 2026, REGENXBIO Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the offer and sale of 10,003,889 shares (the "Firm Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a price to the public of $9.00 per…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RGNX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| License & Service | $103.8M | 96.1% | +462.4% |
| Abb Vie Development Milestone | $100.0M | 92.6% | — |
| Service | $4.2M | 3.9% | +44.4% |
| Total Service Revenue | $4.2M | 3.9% | +44.4% |
| Zolgensma & Itvisma Royalties | $3.8M | 3.6% | -79.2% |
| Nippon Shinyaku Services | $3.7M | 3.4% | +36.8% |
| Itvisma Royalties | $2.1M | 1.9% | — |
| Zolgensma Royalties | $1.8M | 1.6% | -90.5% |
| Other Service Revenue | $458,000 | 0.4% | +163.2% |
| Total revenue | $108.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RGNX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | “our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize surabgene lomparvovec (sura-vec, ABBV-RGX-314) and our collaboration with Nippon Shinyaku Co., Ltd. to develop and commercialize RGX-121 (clemidsogene lanparvovec) and RGX-111;” |
| Partner | Nippon Shinyaku | “our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize surabgene lomparvovec (sura-vec, ABBV-RGX-314) and our collaboration with Nippon Shinyaku Co., Ltd. to develop and commercialize RGX-121 (clemidsogene lanparvovec) and RGX-111;” |
| Partner | GlaxoSmithKline | “The pre-existing licenses also include a license agreement Penn entered into with GSK in May 2002, granting a license to certain patents and patent applications, of which we subsequently sublicensed certain rights to from GSK in March 2009.” |
| Partner | AMD (AMD) | “Surabgene lomparvovec (sura-vec, ABBV-RGX-314), which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).” |
| Partner | Novartis Gene Therapies | “In March 2014, we entered into an agreement with AveXis, Inc. (AveXis, now Novartis Gene Therapies) for an exclusive, worldwide commercial license, with rights to sublicense, to the NAV AAV9 vector for the treatment of SMA.” |
| Partner | NOVARTIS AG (NVS) | “Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the Company's license agreement with Novartis Gene Therapies, Inc. (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular atrophy (SMA).” |
| Partner | AveXis | “In March 2014, we entered into an agreement with AveXis, Inc. (AveXis, now Novartis Gene Therapies) for an exclusive, worldwide commercial license, with rights to sublicense, to the NAV AAV9 vector for the treatment of SMA.” |
| Partner | Clearside Biomedical | “Clearside Biomedical, Inc. In August 2019, we entered into an option and license agreement with Clearside for the option to receive an exclusive, worldwide commercial license, with rights to sublicense, to Clearside's SCS Microinjector for the delivery of AAV gene therapies for the treatment of wet AMD, DR, and other conditions for which chronic anti-VEGF treatment is currently the standard of care.” |
| Partner | Healthcare Royalty Management | “In May 2025, we entered into a loan agreement with entities managed by Healthcare Royalty Management, LLC (collectively and with other affiliated entities, HCR).” |
| Partner | Leerink Partners | “In December 2024, we entered into a Sales Agreement with Leerink Partners LLC (Leerink) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through Leerink, acting as our sales agent (the Leerink ATM Program).” |
| Partner | ROCKET PHARMACEUTICALS, INC. (RCKT) | “Prior to the maturity date, interest and principal under the 2025 Royalty Bond shall be paid quarterly to HCR solely using proceeds received from certain specified royalties, milestone payments, license fees and other consideration payable to the Company under specified license agreements (collectively, the Royalty Interest), including (i) the Novartis License for Zolgensma and Itvisma, (ii) the collaboration and …” |
| Partner | Ultragenyx Pharmaceutical Inc. (RARE) | “Prior to the maturity date, interest and principal under the 2025 Royalty Bond shall be paid quarterly to HCR solely using proceeds received from certain specified royalties, milestone payments, license fees and other consideration payable to the Company under specified license agreements (collectively, the Royalty Interest), including (i) the Novartis License for Zolgensma and Itvisma, (ii) the collaboration and …” |
Quoted from the company's 10-K filed Mar 5, 2026.
Companies that name RGNX in their SEC reports
| Relationship to RGNX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Voyager Therapeutics, Inc. (VYGR) | 10-K Mar 9, 2026 | “For example, adverse events in gene therapy clinical trials, such as the more recent deaths in trials conducted by both Sarepta Therapeutics, Inc. and Capsida Biotherapeutics, Inc., respectively, and the occurrence of a brain tumor after an experimental gene therapy by REGENXBio Inc., may adversely impact how gene therapy is perceived by collaborators, regulators, and the investment community.” |
| partner | Ocugen, Inc. (OCGN) | 10-K Mar 4, 2026 | “We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma Inc., MeiraGTx Holdings plc in partnership with Janssen Pharmaceuticals, Inc., Nanoscope Therapeutics Inc., REGENXBIO Inc., Novartis AG, F.” |
| partner | uniQure N.V. (QURE) | 10-K Mar 2, 2026 | “In June 2020, uniQure France entered into an agreement, subsequently amended in June 2021, with Regenxbio for an exclusive (in the field of using AAV9 to expression of the GRIK2 gene in humans (the "Field")), sublicensable, royalty-bearing, worldwide license under Regenxbio's interest in EU patent application 19185533.7 (the "Foreground Patents") and related patents, as well as patents covering inventions develope…” |
| partner | Ultragenyx Pharmaceutical Inc. (RARE) | 10-K Feb 18, 2026 | “Please see "—License and Collaboration Agreements—Clinical Product Candidates—REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” |
RGNX customer concentration
In the period ended Dec 31, 2025, 2 direct customers each accounted for at least 10% (50%, 49%) of revenue, per the company's 10-K filed Mar 5, 2026. The company does not name them.
RGNX company outlook (results filed Aug 6, 2026)
- “FINANCIAL GUIDANCE REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $105.5 million as of June 30, 2026, along with the $100.0 million milestone payment and $107.8 million estimated net offering proceeds received in July 2026, are sufficient to fund operations into Q4 2027.”
- “This cash runway guidance is based on the Company's current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes any additional potential dilutive or non-dilutive funding opportunities.”
Quoted word-for-word from the SEC 8-K results press release.
RGNX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.30 | $-0.97 | −$0.33 | $15.7M | 9 |
| Next quarter (ends Dec 2026) | $-0.98 | $-0.68 | −$0.30 | $37.9M | 9 |
| Current fiscal year (ends Dec 2026) | $-3.49 | $-2.79 | −$0.70 | $166.0M | 9 |
| Next fiscal year (ends Dec 2027) | $-2.97 | $-2.54 | −$0.43 | $205.0M | 9 |
RGNX options: expected move
Options price a move of about ±47.2% (±$3.43) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±11.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 243.9% | ±47.2% |
| Jan 15, 2027 | 78 | 144.2% | ±60.7% |
| Apr 16, 2027 | 169 | 163.0% | ±83.1% |
30-day implied volatility 129.9% vs 64.5% realized over the last 30 trading days. Put/call ratio (volume) 0.21. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 20:59 UTC)
| Price | USD 7.41 |
|---|---|
| Change | ▲ 2.35% (up) |
| Previous Close | USD 7.24 |
| Open | USD 7.36 |
| Day Range | USD 7.21 – 7.63 |
| 52-Week Range | USD 5.46 – 16.19 |
| Volume | 1,033,249 shares |
| Market Cap | $489.16M |
| Exchange | NMS |
Technical Analysis (RGNX)
Nexqual's technical model rates RGNX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 20:59 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.21 (neutral) |
| vs SMA50 | Below (USD 8.06) |
| MACD | -0.3 (negative) |
Analyst Ratings (RGNX)
Wall Street analysts rate RGNX "Buy" based on 12 analysts, with a mean price target of USD 23.58 (range USD 10–50), per Nexqual as of October 29, 2026 at 20:59 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 23.58 |
| High Target | USD 50 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (RGNX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.3 |
| Revenue Estimate | $15.70M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.43 vs est -0.11 ▲ beat |
| 2026-03-31 | USD -1.72 vs est -1.41 ▼ miss |
| 2025-12-31 | USD -1.3 vs est -0.84 ▼ miss |
| 2025-09-30 | USD -1.2 vs est -1.3 ▲ beat |
Source: Nexqual, October 29, 2026 at 20:59 UTC.
Financials & Fundamentals (RGNX)
| Total Revenue | $174.48M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +405.70% |
| Gross Margin | -44.95% |
| Operating Margin | +27.09% |
| Profit Margin | -112.58% |
| ROE | -137.63% |
| Debt / Equity | 3.49 |
| Current Ratio | 2.86 |
| Total Cash | $105.52M |
| Total Debt | $250.46M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$249.67M (-143.1% of revenue) |
Source: Nexqual, October 29, 2026 at 20:59 UTC.
Financial Health Score (RGNX)
Nexqual rates REGENXBIO Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:59 UTC.
| Growth | Strong — Revenue +105% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin -45%, operating -94% (last 12 months) |
| Balance Sheet | Weak — $106M cash vs $250M debt |
| Cash Flow | Weak — FCF negative: -$250M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -274%, ROA -50.8% (last 4 quarters, SEC) |
Ownership (RGNX)
| Insider Ownership | +6.55% |
|---|---|
| Institutional Ownership | +65.07% |
| Shares Outstanding | 66.01M |
| Float | 57.23M |
| Short % of Float | +16.10% |
Source: Nexqual, October 29, 2026 at 20:59 UTC.
Leadership (RGNX)
REGENXBIO Inc. is led by Mitchell Chan, Executive VP & CFO, per Nexqual as of October 29, 2026 at 20:59 UTC.
| Executive VP & CFO | Mitchell Chan |
|---|---|
| Executive VP of Product Development & CTO | Craig Malzahn |
| Executive VP & Chief Scientific Officer | Olivier Danos |
Major Backers & Investors (RGNX)
Notable institutional backers of REGENXBIO Inc. include Redmile Group, LLC, JPMorgan, Morgan Stanley, according to Nexqual as of October 29, 2026 at 20:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Redmile Group, LLC | 6.62% |
| JPMorgan | 3.35% |
| Morgan Stanley | 2.96% |
| Goldman Sachs | 2.15% |
| AQR Capital Management, LLC | 2.09% |
| Marshall Wace LLP | 1.95% |
| Fidelity | 1.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.69% |
| Vanguard Group | 5.24% |
| State Street | 4.5% |
Source: Nexqual, October 29, 2026 at 20:59 UTC.
From REGENXBIO Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform.
- Together, with our in-house, U.S.-based manufacturing and end-to-end capabilities, we are excited about the prospect of bringing these assets to commercial stage and continuing to leverage our NAV Technology Platform to generate additional promising gene therapies.
- Our NAV Technology Platform has consisted of exclusive rights to a large portfolio of AAV vectors (NAV Vectors), including commonly used AAV8 and AAV9.
- Since our founding, we have built a team of experts in research and development, preclinical and clinical development, scalable manufacturing and commercialization, enabling us to have integrated, end-to-end capabilities.
Partnerships
- Our investigational gene therapies include: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
- We are developing surabgene lomparvovec (sura-vec, ABBV-RGX‑314) in collaboration with AbbVie as a potential one-time treatment for wet AMD and DR.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.
- Our planned clinical trials may be substantially delayed, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
- We face significant competition and there is a possibility that our competitors may achieve regulatory approval before us or develop products that are safer, less expensive or more convenient or effective than ours.
- We are required to comply with ongoing manufacturing regulatory requirements and regulatory health authorities routinely conduct inspections of our product manufacturing and testing facilities that may result in findings that cause a delay or disrupt our drug development and commercialization efforts.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:59 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt